Digital PCR for Rare Mutation Detection

Digital PCR (dPCR) is a leading technology for detection and quantification of rare mutations and target sequences in cancer and disease. With the Applied Biosystems QuantStudio Absolute Q Digital PCR System, researchers can quickly and easily quantify relevant targets by leveraging a simple dPCR workflow backed by the trusted performance of TaqMan probe-based assays.

dPCR can detect rare targets with mutation allele frequencies (MAFs) as low as 0.1%

Precise quantification of rare, single-nucleotide polymorphisms (SNPs) and other mutations over background requires highly sensitive analysis. Because dPCR effectively enriches low-level targets by partitioning samples into individual microchamber reactions, it is uniquely suited for applications requiring quantitative rare target detection, such as liquid biopsy analysis.

Technical note: Rare-target quantification on the the Absolute Q Digital PCR System

dPCR increases sensitivity for rare target detection over conventional method

Absolute quantification using dPCR eliminates the need for a standard curve, improving both the accuracy and reproducibility of rare-target concentration measurement. dPCR also enables detection of ultra-rare target by leveraging pooling data to overcome limitations of sample input volume and concentration.

Poster: Precision genotyping for EGFR+ NSCLC using multiplexed dPCR on cell-free DNA
Technical Note: Improve sensitivity for rare targets by pooling digital PCR data

dPCR is an established technology for rare mutation analysis

With the ability to detect very low fractions of mutant targets in a background of abundant wild-type targets, dPCR is a technology of choice for cancer and genetic disease researchers.

Read QuantStudio Absolute Q dPCR publications ›

dPCR enables precise quantification of ctDNA from liquid biopsies

Characterizing ctDNA helps researchers detect cancer early, measure therapeutic response, quantify residual tumor burden, and monitor emerging resistance to potential therapies. Because ctDNA fragments are typically short and very low in concentration, the sensitivity of dPCR makes it an ideal tool for ctDNA studies.

Webinar: dPCR in liquid biopsy for management and detection of cancer

Absolute Q Liquid Biopsy dPCR assays enable reproducible, specific detection of known somatic mutations. Each predesigned assay has been validated using controls to detect down to 0.1% variant allele frequency in genes relevant for cancer research.

Absolute Q Liquid Biopsy dPCR assays are:

• Simple—preformulated and verified assay in a single tube, enabling you to immediately start your research
• Fast—minimal hands-on time; results in 90 minutes when used with the QuantStudio Absolute Q Digital PCR System
• Highly Sensitive—detect down to 0.1% variant allele frequency
• Robust—analyze your data with confidence using verified assays backed by a performance guarantee*
   

Download flyer

Can’t find the assay you’re looking for? Design a digital PCR assay with a self service tool or get help with our design services.

Launch assay design hub ›

Adapt an existing TaqMan assay for use on the QuantStudio Absolute Q Digital PCR System.

Explore assays ›
Quick reference guide